
1. Nat Med. 2020 Oct;26(10):1602-1608. doi: 10.1038/s41591-020-1005-2. Epub 2020 Aug
3.

Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium
falciparum kelch13 R561H mutant parasites in Rwanda.

Uwimana A(1), Legrand E(2), Stokes BH(3), Ndikumana JM(4), Warsame M(5), Umulisa 
N(6)(7), Ngamije D(8), Munyaneza T(9), Mazarati JB(9), Munguti K(10), Campagne
P(11), Criscuolo A(11), Ariey F(12), Murindahabi M(13), Ringwald P(14), Fidock
DA(3)(15), Mbituyumuremyi A(4), Menard D(16).

Author information: 
(1)Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC),
Kigali, Rwanda. Aline.Uwimana@rbc.gov.rw.
(2)Malaria Genetics and Resistance Unit, Institut Pasteur, Paris, France.
(3)Department of Microbiology and Immunology, Columbia University Irving Medical 
Center, New York, USA.
(4)Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC),
Kigali, Rwanda.
(5)University of Gothenburg, Gothenburg, Sweden.
(6)Maternal and Child Survival Program/JHPIEGO, Baltimore, MD, USA.
(7)Impact Malaria Rwanda, Kigali, Rwanda.
(8)Ministry of Health, Kigali, Rwanda.
(9)National Reference Laboratory (NRL), BIOS /Rwanda Biomedical Centre (RBC),
Kigali, Rwanda.
(10)US President's Malaria Initiative, Kigali, Rwanda.
(11)Hub de Bioinformatique et Biostatistique-Département Biologie
Computationnelle, Paris, France.
(12)INSERM 1016, Institut Cochin, Service de Parasitologie-Mycologie, Hôpital
Cochin, Université de Paris, Paris, France.
(13)Roll Back Malaria for West and Central Africa, Kigali, Rwanda.
(14)Global Malaria Programme, World Health Organization, Geneva, Switzerland.
(15)Division of Infectious Diseases, Department of Medicine, Columbia University 
Irving Medical Center, New York, NY, USA.
(16)Malaria Genetics and Resistance Unit, Institut Pasteur, Paris, France.
dmenard@pasteur.fr.

Artemisinin resistance (delayed P. falciparum clearance following
artemisinin-based combination therapy), is widespread across Southeast Asia but
to date has not been reported in Africa1-4. Here we genotyped the P. falciparum
K13 (Pfkelch13) propeller domain, mutations in which can mediate artemisinin
resistance5,6, in pretreatment samples collected from recent
dihydroarteminisin-piperaquine and artemether-lumefantrine efficacy trials in
Rwanda7. While cure rates were >95% in both treatment arms, the Pfkelch13 R561H
mutation was identified in 19 of 257 (7.4%) patients at Masaka. Phylogenetic
analysis revealed the expansion of an indigenous R561H lineage. Gene editing
confirmed that this mutation can drive artemisinin resistance in vitro. This
study provides evidence for the de novo emergence of Pfkelch13-mediated
artemisinin resistance in Rwanda, potentially compromising the continued success 
of antimalarial chemotherapy in Africa.

DOI: 10.1038/s41591-020-1005-2 
PMCID: PMC7541349
PMID: 32747827 

